A randomized trial of Bacteroides fragilis 839 on preventing chemotherapy-induced myelosuppression and gastrointestinal adverse effects in breast cancer patients

CONCLUSIONS: These findings suggest that BF839 has the potential to effectively mitigate myelosuppression and gastrointestinal toxicity associated with chemotherapy in breast cancer patients.PMID:38494684 | DOI:10.6133/apjcn.202403_33(1).0003

Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Ting Zeng Yu-Hong Deng Chu-Hui Lin Xin-Xin Chen Hai-Xia Jia Xiao-Wu Hu Ting Xia Yun Ling Le-Hong Zhang Teng-Fei Cao Source Type: research